FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL										
OMB Number:	3235-02									

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  BOGER JOSHUA S					V	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [ VRTX ]									tionship of Reporting all applicable) Director Officer (give title		10% O Other (		
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST					08	3. Date of Earliest Transaction (Month/Day/Year) 08/31/2011									below)			below)	
(Street) CAMBRIDGE MA 02139				-   4. I -	4. If Amendment, Date of Original Filed (Month/Day/Year)								. Indivine)	·					
(City)	(Si	•	(Zip)																
1. Title of Security (Instr. 3) 2. Trans		2. Transac	tion	on 2A. Deeme		ed Date,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			5. Amou Securitie Benefici Owned F		int of es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	action(s) 3 and 4)			(Instr. 4)
Common Stock 08,			08/31/2	2011	011			M		4,000	A	\$24.6	56	<b>73</b> 1	1,395		D		
Common Stock 08/3			08/31/2	2011	)11			S <sup>(1)</sup>		3,100	D	\$45.59	(2)(3)	728	8,295		D		
Common Stock 08/31/2			2011	11			S <sup>(1)</sup>		900	D	\$46.27	5.27(3)(4)		727,395		D			
Common Stock												13	13,286		I	401(k)			
		T	able I								posed of				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/Y		cisable and	7. Title a Amount Securitie Underlyi	nd of es ng /e Security	8. De Se	Price of erivative ecurity estr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	i G	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amoun or Numbe of Shares	r					
Stock Option	\$24.66	08/31/2011			M			4,000	(5	)	12/10/2011	Commor Stock			\$0.00	52,946		D	

### **Explanation of Responses:**

- $1.\ Transaction\ made\ pursuant\ to\ Dr.\ Boger's\ company\ approved\ trading\ plan\ under\ Rule\ 10b5-1.$
- 2. Open market sales reported on this line occurred at an weighted average price of \$45.59 (range \$45.08 to \$45.99).
- 3. Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Open market sales reported on this line occurred at a weighted average price of \$46.27 (range \$46.02 to \$46.51).
- 5. Fully vested.

# Remarks:

<u>Valerie L. Andrews, Attorney-</u> <u>In-Fact</u>

09/01/2011

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.